stockrow
Friday 6 November 2026
Export INKT’s income statement to Excel — free account
MiNK Therapeutics, Inc.
INKT Healthcare Biotechnology
- EPS
- +41.5%
- Free cash flow
- −32.7%
Quarter to June 2026, against a year earlier
10.35
0.30
+2.99%
Follow INKT
Alert me
MiNK Therapeutics, Inc. (INKT) P/E ratio
MiNK Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2019 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| PLRX Pliant Therapeutics, Inc. compare | n/m |
| INKT MiNK Therapeutics, Inc. | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| VRCA Verrica Pharmaceuticals Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)